View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 23, 2017

Atara and Merck to investigate ATA129 + Keytruda for EBV-associated NPC

Biopharmaceutical firm Atara Biotherapeutics has entered a clinical trial collaboration agreement with Merck to evaluate the combination of its ATA129 with Keytruda (pembrolizumab) for the treatment of patients with nasopharyngeal carcinoma (NPC) associated with Epstein-Barr virus (EBV).

Biopharmaceutical firm Atara Biotherapeutics has entered into a clinical trial collaboration agreement with Merck to evaluate the combination of its ATA129 with Keytruda (pembrolizumab) for the treatment of patients with nasopharyngeal carcinoma (NPC) associated with Epstein-Barr virus (EBV).

ATA129 is an investigational, allogeneic EBV-specific cytotoxic T-lymphocytes (CTL), while Merck's Keytruda is an anti-programmed death receptor-1 (anti-PD-1) therapy.

The safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ATA129 + Keytruda will be assessed in a Phase I/II trial set to begin next year.

Under the agreement, Atara Bio will sponsor the trial, which will include patients with platinum-resistant or recurrent EBV-associated NPC.

"The investigational therapy was previously assessed in Phase I and II trials as a monotherapy in patients with various EBV-positive malignancies."

Atara Bio chief scientific officer and research and development executive vice-president Chris Haqq said: “Both ATA129 and Keytruda have shown evidence of objective radiographic responses in NPC, and there is a strong biologic rationale to combine these therapies as their complementary mechanisms of action may enhance the anti-tumour activity."

ATA129 induces T-cells to identify EBV antigens that are expressed in the cells of some liquid and solid tumours.

The investigational therapy was previously assessed in Phase I and II trials as a monotherapy in patients with various EBV-positive malignancies.

The trial also included 14 patients with chemotherapy refractory, metastatic NPC and showed that EBV-CTLs expanded after treatment and without the associated lympho-depleting chemotherapy.

According to the data from recent studies, EBV upregulates PD-L1 transcription in related solid tumours such as NPC and gastric cancer, which provides scope for combination with anti-PD-1 therapies.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena